BriaCell Therapeutics has initiated a Phase 3 study of Bria-IMT in advanced metastatic breast cancer. The study, which is expected to enroll 354 patients, could result in full approval and marketing authorization for Bria-IMT if the results are positive. The study's primary endpoint is overall survival in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice. The study initiation follows FDA Fast Track designation and earlier supportive Phase 2 safety and efficacy data.